The investment portfolio “Biotech & Pharma” is an opportunity to earn money alongside with the latest achievements in the field of medicine and genetics. This portfolio focuses both on investments in the most advanced research and developments, as well as investments in already approved and effective drugs.

The basis of this thematic portfolio consists of shares of public companies engaged in research, development and production of the latest drugs and methods of treatment and diagnosis of diseases. Main directions:

  • Orphan Drugs
  • Molecular Immunotherapy
  • Vaccines
  • Genome editing
  • Laboratory Equipment
  • Transplantation
Investment type Individual portfolio
Asset class Shares
Currency USD
Minimum investment amount 200 000 USD
Geographical focus Global markets

The current investment portfolio type is formed by the managers of Rietumu Asset Management and in different periods of time may include shares of 25-40 issuing companies.

Examples of companies in this area

1. CRSP - Crispr Therapeutics

A Swiss company, which leads the development of genome editing, employing the eponymous CRISPR technology. Such technology allows direct editing of the genome and is a cheaper and simpler compared to other existing technologies. The company has many promising developments and strategic partnerships with companies such as Vertex Therapeutics, Bayer, MaxCyte and others. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

2. ABT - Abbott Laboratories

One of America’s largest multi-brand biopharmaceuticals founded in 1888. The main sources of profit for the company are medical instruments and diagnostic solutions. Abbott was the first company to receive approval for low-cost COVID-19 tests and is also the owner of St Jude Medical, a leading network of pediatric cancer research and treatment clinics. Abbott has a particularly broad portfolio of medicines and drugs for treating, testing, and preventing diabetes.

3. SAGE - Sage Therapeutics

An American biopharmaceutical company founded in 2010 that develops and manufactures drugs for the treatment of diseases of the central nervous system. The main sources of income are medicines for the treatment of major depressive disorders, bipolar disorder and other generalized anxiety disorders. The company is a partner of the larger companies Biogen and Shionogi Inc, which also develop and manufacture drugs for the treatment of diseases of the central nervous system.